Complication rate, functional outcomes, and risk factors associated with carbon ion radiotherapy for patients with unresectable pelvic bone sarcoma

Abstract

Background To the authors' knowledge, carbon ion radiotherapy (CIRT) is one of the few curative treatments for unresectable pelvic bone sarcoma. The current study investigated the complications, functional outcomes, and risk factors of CIRT. Methods Of 112 patients who were treated with CIRT for unresectable pelvic bone sarcoma, the authors enrolled 29 patients who were without local disease recurrence or distant metastasis. The mean follow‐up was 93 months. Complications, functional outcomes, and quality of life scores were assessed. Risk factors were analyzed, including the dose‐volume histogram of the femoral head. Results Femoral head necrosis occurred in approximately 37% of patients, pelvic fractures were reported in 48% of patients, and neurological deficits were noted in 52% of patients. Femoral head necrosis was found to be significantly more prevalent among patients with periacetabular tumors (P = .018). The dose‐volume histogram of the femoral head indicated tolerable volume percentages of the femoral head to be <33% for 40 grays (relative biological effectiveness) and 16% for 60 grays ( relative biological effectiveness). The mean Musculoskeletal Tumor Society score and Toronto Extremity Salvage Score were 53% and 64%, respectively, and the mean EuroQol 5 dimensions questionnaire index was 0.587. Patients aged >50 years and those with periacetabular tumors were found to have significantly lower Toronto Extremity Salvage Scores. Conclusions Femoral head necrosis, pelvic fracture, and nerve damage are common complications with the use of CIRT for pelvic bone sarcoma. To prevent femoral head necrosis, the radiation dose to the femoral head should be kept below the estimated tolerance curve presented in the current study. The functional outcome is nearly equivalent to that of surgery. CIRT may be a promising alternative to surgery for patients with unresectable pelvic bone sarcoma.

Risk factors for 30‐day soft tissue complications after pelvic sarcoma surgery: A National Surgical Quality Improvement Program study

“…Pelvic location has been described as a risk factor for worse postoperative outcomes and higher recurrence rates, and therefore its management remains challenging 5,6 . Unlike appendicular tumors, which are often detected early due to their mass effect, pelvic bone, and ST sarcomas can remain hidden until symptomatic and present as a more aggressive tumor 4,5,7 …”

Rectal dose-sparing effect with bioabsorbable spacer placement in carbon ion radiotherapy for sacral chordoma: dosimetric comparison of a simulation study

“…To date, there have been a few reports on the effectiveness and safety of spacer placement [ 6–8 ]. However, there is a risk of infection due to leaving the Gore-Tex sheets spacer after the C-ion RT [ 7 ].…”

Sacral-Nerve-Sparing Planning Strategy in Pelvic Sarcomas/Chordomas Treated with Carbon-Ion Radiotherapy

“…The LEM-I prescription doses and dose constraints were adapted with respect to corresponding mMKM prescription doses as per the translation schema provided by Fossati et al [28]. The median overall treatment time was 26 days (range of [22][23][24][25][26][27][28][29][30][31][32]. During the course of treatment, at least two re-evaluation CT scans were performed to evaluate the robustness of target and OAR dose constraints.…”